


What is DISCOVERY AT SCALE?

# **Multiplying** the rate of biomarker discovery to **maximize** drug development success

A drug candidate with an associated biomarker is 2–10x more likely to obtain FDA approval.  $\!\!^1$ 

Biomarkers help to stratify patient populations by elucidating the involvement of specific genes, proteins, and molecular alterations that give rise to their disease state. Therapies can then be aligned with patients most likely to benefit.

Bioanalytical methods have been limited in their ability to probe thibiology at a speed and scale that yields rapid impact, particularly when it comes to small molecule biomarker discovery - until now.




### **Sapient Biomarker Discovery Platform**

#### rLC-MS Profiling:

Rapid discovery with untargeted, ultra high throughput analysis

Sapient's next generation rapid liquid chromatography-mass spectrometry (rLC-MS) systems capture and measure thousands of small molecule biomarkers, including uncharacterized compounds, in any biological sample.






#### **Human Biology Database:**

Rapid validation with population-level biomarker insights

Sapient has built an expansive proprietary repository of data from hundreds of thousands of biosamples from individuals around the world - all of which have been assayed via our rLC-MS systems. Cohorts include:





This biomarker has already been measured in the samples in our database!

### Biocomputational Prioritization:

Identify key biomarkers in your biosamples

Leveraging biostatistical analysis and advanced algorithms, Sapient's data scientists can rapidly pinpoint sensitive and specific biomarkers of biological processes, disease progression, and/or drug responsiveness. This comprehensive analysis integrates high-dimensional data from:

Produced by interactions between genes, transcripts, and proteins, internal organs

posures, small molecule biomarkers are uniquely suited to depict phenotype

Non-invasively captured: small molecules pass from local

Give early insight into disease mechanisms: reflect biological

**Provide insight into human biology:** capture direct biomarkers of target engagement, indirect biomarkers of biological effects,



### 85%+

novel discoveries - the majority of molecules we capture are unknown

### Database Validation:

Analyze the *same* biomarker in >100,000s biosamples

Sapient's longitudinal Human Biology Database can be readily tapped to confirm the biomarker findings in a large-scale, population-based cohort, providing the statistical power to validate the specificity and sensitivity of your biomarker. Sample data is also linked to data on individuals.



Individuals in our database have been clinically followed for >10-30 years



## Does the biomarker hold diagnostic promise?

Sapient can support translation of your biomarker into an assay for use in clinical trials or CLIA settings.

# Discover more to amplify the scale of your drug pipeline's success

Drug development shouldn't take more than a decade and over a billion dollars, and still fail greater than 80% of time. **Biomarker-driven drug development can shift this paradigm**.

Earlier diagnosis and intervention, optimized patient selection, smaller clinical trials, precise dosing and timing of treatments: all of this is possible with the right biomarkers. Sapient is here to help you find them faster, and accelerate the transformation of your pipeline's cost, efficiency, and value.

By discovering biomarkers of biological processes, disease progression, and drug responsiveness, we can identify the:



RIGHT DISEASE

Elucidate targets, detect disease early, predict progression



RIGHT PATIENT

Stratify patients, enrich clinical trials



Confirm target engagement, optimize dosing

## Start your study today

Get in touch with Sapient the following ways:

Visit: sapient.bio | Email: discover@sapient.bio | Call: 858.290.7010

